Navigation Links
Using amphetamines may increase risk of Parkinson's disease
Date:2/20/2011

ST. PAUL, Minn. New research shows people who have used amphetamines such as benzedrine and dexedrine appear to be at an increased risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 63rd Annual Meeting in Honolulu April 9 to April 16, 2011.

Benzedrine and Dexedrine are amphetamines often prescribed to increase wakefulness and focus for people with attention deficit hyperactivity disorder and narcolepsy, a disorder that can cause excessive daytime sleepiness and sudden attacks of sleep. They are also used to treat traumatic brain injuries.

The study involved 66,348 people in northern California who had participated in the Multiphasic Health Checkup Cohort Exam between 1964 and 1973 and were evaluated again in 1995. The average age of the participants at the start of the study was 36 years old. Of the participants, 1,154 people had been diagnosed with Parkinson's disease by the end of the study.

Exposure to amphetamines was determined by two questions: one on the use of drugs for weight loss and a second question on whether people often used Benzedrine or Dexedrine. Amphetamines were among the drugs commonly used for weight loss when this information was collected.

According to the study, those people who reported using Benzedrine or Dexedrine were nearly 60 percent more likely to develop Parkinson's than those people who didn't take the drugs. There was no increased risk found for those people who used drugs for weight loss.

"If further studies confirm these findings, the potential risk of developing Parkinson's disease from these types of amphetamines would need to be considered by doctors before prescribing these drugs as well as be incorporated into amphetamine abuse programs, including illicit use," said study author Stephen K. Van Den Eeden, PhD, with the Division of Research at Kaiser Permanente Northern California in Oakland, Calif.

Van Den Eeden explained that amphetamines affect the release and uptake of dopamine, the key neurotransmitter involved in Parkinson's disease. He explained that more research needs to be completed to confirm the association and learn more about possible mechanisms.


'/>"/>

Contact: Rachel Seroka
rseroka@aan.com
651-695-2738
American Academy of Neurology
Source:Eurekalert

Related medicine news :

1. A new high-resolution method for imaging below the skin using a liquid lens
2. Using Cell Phones Might Evoke Emotions, Study Suggests
3. Children in public housing play outdoors more
4. Using chlorhexidine gluconate baths to reduce hospital-acquired infections
5. UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife
6. Researchers identify the genotype of disorders causing cardiac sudden death syndrome
7. Using pharmacist-directed service improves quality of care for patients
8. Breathing easy: LSU biochemists offer first 3-D model of asthma-causing inflammation enzyme
9. Health-care systems not using best evidence in decision-making
10. Model predicts a drugs likelihood of causing birth defects
11. 2 people receive kidney transplants in pilot program using CMU software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... ... Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. ... distinguish between corrective action (CA) and preventive action (PA)? , The methods share ...
(Date:2/17/2017)... Tx (PRWEB) , ... February 17, 2017 , ... ... revenue cycle management services, announced today that Karen Pilley has been promoted to ... is critical in today’s shifting healthcare paradigm – a shift that demands the ...
(Date:2/17/2017)... GA (PRWEB) , ... February 17, 2017 , ... Like ... to reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), ... been a key focus area for hospitals across the nation. While many providers are ...
(Date:2/16/2017)... York, New York (PRWEB) , ... February 17, ... ... work and determination. After what took over 10 years of research, development and ... technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ingredients ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection ... patient care, NWH has achieved Magnet® recognition for the second time, ... 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Ontario , Feb. 16, 2017  Aralez Pharmaceuticals ... global specialty pharmaceutical company, today announced that executive management ... Conference to be held February 22-23, 2017. Adrian ... of the Company at 1:35 p.m. local time on ... and audio archive for the event may be accessed ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
Breaking Medicine Technology: